[EGRX] Eagle Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 730.08 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 80.93 Change: 5.35 (7.08%)
Ext. hours: Change: 0 (0%)

chart EGRX

Refresh chart

Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was found

Fundamental Ratios
Shares Outstanding15.64 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 526.88% Sales Growth - Q/Q548.38% P/E
P/E To EPS Growth P/S14.45 P/BV7.1 Price/Cash Per Share
Price/Free Cash Flow-52.57 ROA1.66% ROE2.09% ROI
Current Ratio4.8 Quick Ratio4.72 Long Term Debt/Equity Debt Ratio0.26
Gross Margin71.95% Operating Margin2.84% Net Profit Margin4.26% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities55.29 M Cash From Investing Activities3.95 M Cash From Operating Activities17.96 M Gross Profit30.36 M
Net Profit19.7 M Operating Profit20.09 M Total Assets129.93 M Total Current Assets129.79 M
Total Current Liabilities27.05 M Total Debt Total Liabilities27.05 M Total Revenue36.31 M
Technical Data
High 52 week83.86 Low 52 week47.5 Last close48.48 Last change-0.43%
RSI39.15 Average true range1.88 Beta1.23 Volume253.51 K
Simple moving average 20 days-5.15% Simple moving average 50 days-17.66% Simple moving average 200 days-25.08%
Performance Data
Performance Week-3.89% Performance Month-12.33% Performance Quart-39.85% Performance Half-27.36%
Performance Year-14.69% Performance Year-to-date-9.25% Volatility daily4.58% Volatility weekly10.25%
Volatility monthly21% Volatility yearly72.74% Relative Volume311.49% Average Volume267.9 K
New High New Low

News

2019-03-12 10:26:50 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-03-01 06:42:51 | Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 14:44:04 | Eagle Pharmaceuticals Inc EGRX Q4 2018 Earnings Conference Call Transcript

2019-02-28 06:50:00 | Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results

2019-02-28 06:30:00 | Eagle Pharmaceuticals, Inc. to Host Earnings Call

2019-02-21 11:06:34 | Is Eagle Pharmaceuticals, Inc.’s NASDAQ:EGRX ROE Of 15% Impressive?

2019-02-21 10:31:03 | Analysts Estimate Eagle Pharmaceuticals EGRX to Report a Decline in Earnings: What to Look Out for

2019-02-19 16:30:00 | Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

2019-02-18 10:30:03 | Earnings Preview: Eagle Pharmaceuticals EGRX Q4 Earnings Expected to Decline

2019-02-14 09:10:02 | Should Value Investors Buy Eagle Pharmaceuticals EGRX Stock?

2019-02-08 08:04:04 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-01-15 08:03:38 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-01-09 08:05:36 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-01-08 08:05:14 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-01-04 06:51:45 | Does Eagle Pharmaceuticals, Inc.’s NASDAQ:EGRX CEO Pay Matter?

2019-01-02 07:00:00 | Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference

2018-12-25 08:04:32 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-12-20 08:06:10 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-12-18 08:06:42 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-12-16 22:49:15 | Hedge Funds Are Selling Eagle Pharmaceuticals Inc EGRX

2018-12-06 08:06:39 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-27 06:50:00 | Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome ARS

2018-11-26 09:05:21 | Investors Are Undervaluing Eagle Pharmaceuticals Inc NASDAQ:EGRX By 28.8%

2018-11-24 08:06:43 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-20 08:06:32 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-19 07:00:00 | Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

2018-11-17 08:04:30 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-16 04:32:09 | Moving Average Crossover Alert: Eagle Pharmaceuticals EGRX

2018-11-05 08:06:36 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-01 16:00:00 | Edited Transcript of EGRX earnings conference call or presentation 1-Nov-18 12:30pm GMT

2018-11-01 10:41:02 | Eagle Pharmaceuticals EGRX Q3 Earnings Match Estimates

2018-11-01 08:21:18 | Eagle Pharmaceuticals: 3Q Earnings Snapshot

2018-11-01 08:04:01 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-11-01 06:50:00 | Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

2018-10-30 06:50:00 | Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization

2018-10-30 06:45:00 | Eagle Pharmaceuticals Announces Results of Study for Fulvestrant

2018-10-25 17:00:00 | Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018

2018-10-23 08:06:38 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-10-23 07:25:00 | Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated Expectations, Analyst Ratings

2018-10-19 09:28:57 | Is Eagle Pharmaceuticals Inc NASDAQ:EGRX Attractive At Its Current PE Ratio?

2018-10-08 08:06:38 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-10-03 07:00:00 | Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure

2018-09-27 07:00:00 | Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference

2018-09-26 16:30:00 | Eagle Appoints David Pernock to Position of Chief Operating Officer

2018-09-22 08:04:18 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-09-21 08:04:34 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2018-09-11 10:41:31 | Does Eagle Pharmaceuticals Inc NASDAQ:EGRX Fall With The Market?

2018-09-07 08:32:12 | Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod

2018-09-05 10:21:02 | Agios AGIO Assigns Ex-Celgene Executive to CEO Position